Literature DB >> 6502846

Low-dose direct fibrinolysis in peripheral vascular disease.

B T Katzen, K C Edwards, A S Albert, A van Breda.   

Abstract

One hundred thirty patients underwent low-dose, catheter-directed fibrinolytic therapy for arterial and graft occlusions present for various periods of time. In 65 consecutive patients the therapeutic parameters were identical, and a careful hematologic evaluation was performed. In the subsequent 65 patients, varying doses of fibrinolytic agents were employed. Fibrinolytic therapy was found to be beneficial in a diverse group of clinical situations and in patients whose occlusions had occurred at varying lengths of time. Early study demonstrated that effective fibrinolysis can be achieved at approximately one-twentieth of the systemic level and that systemic effects could be avoided in all patients during 24-hour infusions and in many patients infused up to 96 hours. Bleeding complications occurred only in patients in whom concomitant heparinization was employed, and this was thought to be the causative factor. Therapeutic success and avoiding complications are strongly dependent on close monitoring of patients and joint decision making by the vascular surgeon and radiologist.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502846     DOI: 10.1067/mva.1984.avs0010718

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

Review 1.  Managing acute limb ischaemia.

Authors:  W B Campbell; T R Magee
Journal:  BMJ       Date:  1989-08-26

2.  Treating claudication.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-18

3.  Venous gangrene of the upper extremity.

Authors:  B M Smith; G W Shield; D H Riddell; J D Snell
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

Review 4.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 5.  Use of thrombolytic drugs in non-coronary disorders.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.